We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > XCOPRI

News List

Global adult epilepsy market to reach $8.35 billion by 2023: GlobalData expresspharma
July 09, 2021
The adult epilepsy market is expected to grow from $5.82 billion in 2020 to $8.35 billion by 2030 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 3.7 per cent, according to GlobalData.
FDA Approves XCOPRI for Partial-Onset Seizures in Adult Patients americanpharmaceuticalreview
December 17, 2019
The U.S. Food and Drug Administration (FDA) approved XCOPRI (cenobamate) for the treatment of partial-onset seizures in adult patients.
FDA approves new treatment for adults with partial-onset seizures fda
November 26, 2019
The U.S. Food and Drug Administration approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults.